Adult medulloblastoma in an Australian population
Sagun Parakh(Australian Research Council), Hui Gan(Austin Hospital), Rosemary Harrup(University of Tasmania), Daniel Roos(Royal Adelaide Hospital), Lawrence Cher(Austin Health), Sarah Cain(University of Virginia), Elizabeth Hovey, James Lynam, James R. Whittle(Walter and Eliza Hall Institute of Medical Research), Cecelia Gzell(Australian and New Zealand Intensive Care Society), Elizabeth Ahern(Monash Health), Po-Ling Inglis(Royal Brisbane and Women's Hospital), Peter K. H. Lau(Sir Charles Gairdner Hospital), Kerryn T. Westcott(Olivia Newton-John Cancer Wellness & Research Centre), Sowmya Cheruvu(Sir Charles Gairdner Hospital), Antoinette Anazodo(Sydney Children's Hospital), Andrew Pullar(Princess Alexandra Hospital), Amal Abou‐Hamden(University of Adelaide), Ganesalingam Pranavan(Australian National University), Amy Davies(Monash Health)
Cited by 3
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
The epidermal growth factor receptor variant <scp>III</scp> (<scp>EGFR</scp>v<scp>III</scp>): where wild things are altered
|FEBS Journal|2013|357
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|332